By Sue Reisinger | June 29, 2017
Flexion Therapeutics Inc. has named Mark Levine as its first general counsel and senior vice president. Levine has more than 20 years of corporate legal experience, having previously served as GC at Minerva Neurosciences Inc., assistant GC at athenahealth Inc., and associate GC at Clinical Data Inc., according to his LinkedIn profile.
By Sue Reisinger | June 23, 2017
More of the world's counterfeit goods are produced in China than in any other country—though India leads the way in counterfeit pharmaceuticals—according to a new report.
By Kristen Rasmussen | June 23, 2017
LakePharma has hired a new general counsel, Hajime Tada.
By Kristen Rasmussen | June 21, 2017
Tom Moriarty of CVS is finding himself in Washington, D.C., a lot more these days.
By Amanda Bronstad | June 20, 2017
Monday's landmark decision by the U.S. Supreme Court in "Bristol-Myers Squibb v. Superior Court of California" has already had a massive impact. In mere hours, a judge in Missouri granted a motion for mistrial in a pivotal trial over Johnson & Johnson's baby powder due to the court's decision. Even plaintiffs lawyers concede that "Bristol-Myers" took a hatchet to a lucrative growth area in mass torts: Lawsuits brought on behalf of dozens of individuals in venues considered more favorable to plaintiffs.
By Tony Mauro | June 19, 2017
In a win for the corporate defense bar, the U.S. Supreme Court on Monday tightened jurisdictional rules that determine where companies can be sued.
By Tony Mauro | June 14, 2017
Civil litigators and corporate counsel can almost taste victory in Bristol-Myers Squibb v. Superior Court of California, seen as the term's most important case on jurisdiction.
By Kristen Rasmussen | June 12, 2017
Last week, the U.S. Food and Drug Administration asked Endo Pharmaceuticals Inc. to remove Opana ER, its extended-release version of oxymorphone hydrochloride, from the market after the agency found a likelihood of abuse by crushing up and injecting the pills.
By Jennifer Williams-Alvarez | June 9, 2017
For close to a decade, the Federal Trade Commission has been trying to get its hands on documents from drugmaker Boehringer Ingelheim Pharmaceuticals Inc., resulting in a yearslong dispute over what documents and communications are protected when an in-house counsel is involved.
By Kristen Rasmussen | June 9, 2017
In what the Cherokee Nation described as "an attack on the very sovereignty of our nation," several pharmaceutical distributors and retail pharmacies have asked a federal judge to prevent a lawsuit against them over the opioid addiction epidemic from proceeding in tribal court.
Presented by BigVoodoo
General Counsel Summit is the premier event for in-house counsel, hosting esteemed legal minds from all sectors of the economy.
Join General Counsel and Senior Legal Leaders at the Premier Forum Designed For and by General Counsel from Fortune 1000 Companies
WIPL is the original global forum facilitating women-to-women exchange on leadership and legal issues.
Truly exceptional Bergen County New Jersey Law Firm is growing and seeks strong plaintiff's personal injury Attorney with 5-7 years plaintif...
Shipman is seeking an associate to join our Labor & Employment practice in our Hartford, New Haven, or Stamford office. Candidates shou...
Evergreen Trading is a media investment firm headquartered in NYC. We help brands achieve their goals by leveraging their unwanted assets to...
MELICK & PORTER, LLP PROMOTES CONNECTICUT PARTNERS HOLLY ROGERS, STEVEN BANKS, and ALEXANDER AHRENS